News

Cupron Performance Additives Announces New Applications for Cupron Sinerji™

Innovative antimicrobial solutions provider Cupron®, doing business as Cupron Performance Additives, announces expanded functionality for its recently introduced antimicrobial platform technology Cupron Sinerji.  Initially engineered as a copper-based formulation, Cupron® has now extended Cupron Sinerji’s  performance, cost, and color advantage to all metal ion chemistries commonly used for antimicrobial purposes.  Specifically, Cupron’s new platform technology delivers improved antimicrobial performance across commoditized antimicrobial metal ion types – copper, silver and zinc.

Cupron Sinerji incorporates adjuvants into the metal ion-based formulations, resulting in a custom, flexible technology engineered to harness synergistic effects to meet a wide range of product protection and antimicrobial performance objectives – from US EPA Treated Article Exemptions to unique and differentiated Public Health Claims.  FDA-regulated products may also incorporate customized Cupron Sinerji formulations.

Utilizing adjuvants, the technology delivers heightened efficacy against various organisms, including mold and mildew, improves color performance and increases manufacturing yields. It offers an efficient and adaptable solution for numerous markets and applications, demonstrating its versatility and innovative potential across all polymers and organisms.

“Expensive silver additives cause many brands to limit the amount used during manufacturing, diminishing the antimicrobial potency of the final products,” said Chris Andrews, CEO of Cupron Performance Additives.

Cupron Sinerji also imparts several non-cost benefits as well to a range of metal ion offerings: color flexibility, color stability, production efficiency and an improved sustainability profile across a range of substrates. With Cupron Sinerji, our partners will re-evaluate the economics and applications associated with microbial control and management. We are pleased to be the reason the market will expect more from antimicrobial additives.”

Recent News

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.

05/28/2025

Avera Joins Civica to Help Minimize Risk of Drug Shortages

Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare provider in the Upper Midwest United States, has joined the company in helping protect patients from the impact of drug shortages of essential generic sterile injectable medicines. Drug shortages are a persistent challenge to the